Wedbush Upgrades Zentalis to Outperform on Promising Ovarian Cancer Survival Data

Analysts upgraded Zentalis after DENALI Part 1b data showed median survival of 15.9 months in Cyclin E1-positive platinum-resistant ovarian cancer.